CARLOS BUFORD: Open Payments
NPI 1568629970 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,836 in 33 payments from 15 companies in 2025. Trend: 2023 $1,226 · 2024 $937 · 2025 $1,836
Food & beverage: $1,836
| Company | Payments | Amount |
|---|---|---|
| ABIOMED | 4 | $264 |
| Novo Nordisk Inc | 7 | $206 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $189 |
| AstraZeneca Pharmaceuticals LP | 4 | $161 |
| Lilly USA, LLC | 2 | $147 |
| Amgen Inc. | 4 | $147 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $119 |
| GENZYME CORPORATION | 1 | $119 |
| ViiV Healthcare Company | 1 | $119 |
Products named: NEFFY, Ozempic, OTEZLA, AIRSUPRA, ZEPBOUND, NUZYRA, Auvelity, DUPIXENT.
Industry payments across TX — which companies pay providers there.
